Catalyst Funds Management Pty Ltd Acquires Shares of 20,800 BioMarin Pharmaceutical Inc. $BMRN

Catalyst Funds Management Pty Ltd acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 20,800 shares of the biotechnology company’s stock, valued at approximately $1,236,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Coldstream Capital Management Inc. increased its stake in BioMarin Pharmaceutical by 7.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 11,256 shares of the biotechnology company’s stock valued at $669,000 after buying an additional 769 shares during the period. LSV Asset Management increased its stake in BioMarin Pharmaceutical by 4.3% in the 4th quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock valued at $52,429,000 after buying an additional 36,700 shares during the period. Global Retirement Partners LLC increased its stake in BioMarin Pharmaceutical by 195.0% in the 4th quarter. Global Retirement Partners LLC now owns 3,691 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 2,440 shares during the period. Leonteq Securities AG bought a new stake in BioMarin Pharmaceutical in the fourth quarter worth approximately $340,000. Finally, PSP Research LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter worth approximately $521,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $54.09 on Friday. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $54.56 and a 200 day simple moving average of $56.24. The company has a market cap of $10.45 billion, a P/E ratio of 39.48, a P/E/G ratio of 0.41 and a beta of 0.23. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

Analyst Ratings Changes

Several analysts have commented on BMRN shares. Wells Fargo & Company boosted their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Piper Sandler decreased their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Bank of America decreased their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Loop Capital set a $105.00 target price on shares of BioMarin Pharmaceutical in a research report on Monday, March 2nd. Finally, The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They issued a “neutral” rating and a $69.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.67.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 16,486 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the sale, the executive vice president directly owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. This represents a 17.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregory R. Friberg sold 3,281 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the sale, the executive vice president directly owned 51,818 shares of the company’s stock, valued at approximately $2,790,399.30. This represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 26,093 shares of company stock valued at $1,555,389. 0.85% of the stock is owned by insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.